journal article·2014-07

Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues

Megan L. McCain, Ashutosh Agarwal, Haley W. Nesmith, Alexander P. Nesmith, Kevin Kit Parker

Biomaterials· Volume 35· Issue 21
Publisher page

Abstract

Defining the chronic cardiotoxic effects of drugs during preclinical screening is hindered by the relatively short lifetime of functional cardiac tissues in vitro, which are traditionally cultured on synthetic materials that do not recapitulate the cardiac microenvironment. Because collagen is the primary extracellular matrix protein in the heart, we hypothesized that micromolded gelatin hydrogel substrates tuned to mimic the elastic modulus of the heart would extend the lifetime of engineered cardiac tissues by better matching the native chemical and mechanical microenvironment. To measure tissue stress, we used tape casting, micromolding, and laser engraving to fabricate gelatin hydrogel muscular thin film cantilevers. Neonatal rat cardiac myocytes adhered to gelatin hydrogels and formed aligned tissues as defined by the microgrooves. Cardiac tissues could be cultured for over three weeks without declines in contractile stress. Myocytes on gelatin had higher spare respiratory capacity compared to those on fibronectin-coated PDMS, suggesting that improved metabolic function could be contributing to extended culture lifetime. Lastly, human induced pluripotent stem cell-derived cardiac myocytes adhered to micromolded gelatin surfaces and formed aligned tissues that remained functional for four weeks, highlighting their potential for human-relevant chronic studies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. The future of drug safety testing: expanding the view and narrowing the focus10.1016/j.drudis.2008.11.009 ↗
2. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity10.1016/j.pharmthera.2013.03.005 ↗
3. Cardiotoxicity of cytotoxic drugs10.1016/j.ctrv.2003.07.003 ↗
4. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management10.1161/01.CIR.0000133187.74800.B9 ↗
5. Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model10.1016/j.taap.2012.10.025 ↗
6. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model
7. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation
8. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios
9. Structural requirements for inducing cardiotoxicity by anthracycline antibiotics: studies with neonatal rat cardiac myocytes in culture10.1016/0041-008X(86)90425-4 ↗
10. Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture10.1016/j.biomaterials.2012.04.043 ↗
11. Mechanotransduction: the role of mechanical stress, myocyte shape, and cytoskeletal architecture on cardiac function10.1007/s00424-011-0951-4 ↗
12. Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating10.1242/jcs.029678 ↗
13. The contribution of cellular mechanotransduction to cardiomyocyte form and function10.1007/s10237-012-0419-2 ↗
14. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity10.1016/j.tox.2007.12.006 ↗
15. A history of the role of the hERG channel in cardiac risk assessment10.1016/j.vascn.2013.03.005 ↗
16. Species differences in the activity of the Na(+)-Ca2+ exchanger in mammalian cardiac myocytes10.1113/jphysiol.1995.sp020995 ↗
17. Functional cardiomyocytes derived from human induced pluripotent stem cells10.1161/CIRCRESAHA.108.192237 ↗
18. Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip10.1039/c1lc20557a ↗
19. Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip10.1073/pnas.1304913110 ↗
20. Microfluidic heart on a chip for higher throughput pharmacological studies10.1039/c3lc50350j ↗
21. Micropatterning alginate substrates for in vitro cardiovascular muscle on a chip10.1002/adfm.201203319 ↗
22. Extracellular matrix and growth factors during heart growth10.1023/A:1009806403194 ↗
23. Hydrogels for tissue engineering10.1021/cr000108x ↗
24. Cell-laden microengineered gelatin methacrylate hydrogels10.1016/j.biomaterials.2010.03.064 ↗
25. A biomimetic extracellular matrix for cartilage tissue engineering centered on photocurable gelatin, hyaluronic acid and chondroitin sulfate10.1016/j.actbio.2013.10.005 ↗
26. Transglutaminase crosslinked gelatin as a tissue engineering scaffold10.1002/jbm.a.31431 ↗
27. Mechanical properties of biomimetic tissue adhesive based on the microbial transglutaminase-catalyzed crosslinking of gelatin10.1021/bm034529a ↗
28. Geometric control of cell life and death10.1126/science.276.5317.1425 ↗
29. Cardiomyocyte cultures with controlled macroscopic anisotropy: a model for functional electrophysiological studies of cardiac muscle10.1161/01.RES.0000047530.88338.EB ↗
30. Myocyte shape regulates lateral registry of sarcomeres and contractility10.1016/j.ajpath.2012.08.045 ↗
31. Muscular thin films for building actuators and powering devices10.1126/science.1146885 ↗
32. Vander · 2001
33. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance10.1152/ajpheart.01017.2005 ↗
34. Biohybrid thin films for measuring contractility in engineered cardiovascular muscle10.1016/j.biomaterials.2010.01.079 ↗
35. Role of contraction in the structure and growth of neonatal rat cardiocytes
36. Contraction regulates myosin synthesis and myosin content of cultured heart cells
37. Assessing bioenergetic function in response to oxidative stress by metabolic profiling10.1016/j.freeradbiomed.2011.08.005 ↗
38. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal10.1042/BJ20090934 ↗
39. Bioenergetic function in cardiovascular cells: the importance of the reserve capacity and its biological regulation10.1016/j.cbi.2010.12.002 ↗
40. Quality metrics for stem cell-derived cardiac myocytes10.1016/j.stemcr.2014.01.015 ↗
41. Matrix elasticity directs stem cell lineage specification10.1016/j.cell.2006.06.044 ↗
42. Substrate stiffness affects the functional maturation of neonatal rat ventricular myocytes10.1529/biophysj.107.124545 ↗
43. Integrins and the myocardium10.1161/hh1101.091862 ↗
44. Dance band on the Titanic: biomechanical signaling in cardiac hypertrophy10.1161/01.RES.0000041680.43270.F8 ↗
45. Surface-initiated assembly of protein nanofabrics10.1021/nl100998p ↗
46. Microtextured substrata alter gene expression, protein localization and the shape of cardiac myocytes10.1016/S0142-9612(02)00644-0 ↗
47. Microfabricated grooves recapitulate neonatal myocyte connexin43 and N-cadherin expression and localization10.1002/jbm.a.10083 ↗
48. Nanoscale cues regulate the structure and function of macroscopic cardiac tissue constructs10.1073/pnas.0906504107 ↗
49. The influence of substrate stiffness gradients on primary human dermal fibroblasts10.1016/j.biomaterials.2013.03.075 ↗
50. Close dependence of fibroblast proliferation on collagen scaffold matrix stiffness10.1002/term.136 ↗
51. Enrichment of neonatal rat cardiomyocytes in primary culture facilitates long-term maintenance of contractility in vitro10.1152/ajpcell.00449.2011 ↗
52. Oxygen, oxidative stress, hypoxia, and heart failure10.1172/JCI200524408 ↗
53. Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts10.1161/01.RES.56.3.377 ↗
54. Myocardial oxygen consumption in experimental hypertrophy and congestive heart failure due to pressure overload10.1016/S0002-9149(73)80033-5 ↗
55. Oxidative capacity in failing hearts10.1152/ajpheart.01142.2002 ↗
56. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype10.1152/ajpheart.00819.2012 ↗
57. Microengineered physiological biomimicry: organs-on-Chips10.1039/c2lc40089h ↗
58. Scaling and systems biology for integrating multiple organs-on-a-chip10.1039/c3lc50243k ↗